Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 9/20 | 0.56 |
| ▸ | ADRA1D | P25100 | 8/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 8/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 8/20 | 0.56 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | LIPE | Q05469 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALPG | P10696 | 1/20 | 0.50 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.49 |
| ▸ | CDK1 | P06493 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.49 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL772663 | 0.90 | HTR1A (0.57) | HTR1AADRA1DADRA1AADRA1BTDP1 | |
| SCHEMBL30327643 | 0.85 | LMNA (0.56) | TDP1MAPTL3MBTL1KDM4EPTK2B | |
| SCHEMBL715500 | 0.85 | LMNA (0.56) | TDP1MAPTL3MBTL1KDM4EPTK2B | |
| SCHEMBL339812 | 0.83 | MAPT (0.71) | HTR1AADRA1DADRA1AADRA1BLTA4H | |
| SCHEMBL10541855 | 0.83 | LTA4H (0.54) | HTR1AADRA1DADRA1AADRA1BLTA4H | |
| SCHEMBL23582876 | 0.82 | HTR1A (0.57) | HTR1AADRA1DADRA1AADRA1BLTA4H | |
| SCHEMBL10459133 | 0.82 | HTR1A (0.57) | HTR1AADRA1DADRA1AADRA1BLTA4H | |
| SCHEMBL29847096 | 0.82 | HTR1A (0.57) | HTR1AADRA1DADRA1AADRA1BLTA4H | |
| SCHEMBL7433717 | 0.81 | LTA4H (0.74) | LTA4HEPHX2MAPTL3MBTL1LMNA | |
| SCHEMBL12745447 | 0.81 | HTR1A (0.63) | HTR1AADRA1DADRA1AADRA1BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060748-A1 | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure | ARTESIAN THERAPEUTICS, INC. | 2007-03-15 | — | — | US | disclosed |
| US-20070060748-A1 | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure | ARTESIAN THERAPEUTICS, INC. | 2007-03-15 | — | — | US | disclosed |
| US-20070060748-A1 | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure | ARTESIAN THERAPEUTICS, INC. | 2007-03-15 | — | — | US | disclosed |
| EP-1565472-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND BETA-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | Artesian Therapeutics, Inc. (US) | 2005-08-24 | — | — | EP | disclosed |
| WO-2005026166-A1 | PHYSIOLOGICALLY ACTIVE COMPOSITION, PHARMACEUTICAL COMPOSITION, SUBSTITUTED 1,2-DIHYDRO[2,7] NAPHTHYRIDINES, METHOD FOR THE PRODUCTION AND USE THEREOF | 'CHEMICAL DIVERSITY RESEARCH INSTITUTE', LTD. (RU) | 2005-03-24 | — | — | WO | disclosed |
| WO-2005016885-A2 | COMPOUNDS WITH COMBINED CALCIUM CHANNEL BLOCKER AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITIES FOR TREATMENT OF HEART DISEASE | ARTESIAN THERAPEUTICS, INC. (US) | 2005-02-24 | — | — | WO | disclosed |
| WO-2004050657-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | ARTESIAN THERAPEUTICS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
| WO-2004050657-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | ARTESIAN THERAPEUTICS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060748-A1 | Compounds with mixed pde-inhibitory and beta-adrenergic antagonist or partial agonist activity for treatment of heart failure | ADRB3, PDE3A, PDE3B | HTR1A 773/4885ADRA1D 25/4885ADRA1A 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.